vs
Side-by-side financial comparison of N-able, Inc. (NABL) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
N-able, Inc. is the larger business by last-quarter revenue ($130.3M vs $70.6M, roughly 1.8× Viridian Therapeutics, Inc.\DE). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 11.8%). N-able, Inc. produced more free cash flow last quarter ($20.9M vs $-84.7M).
Able UK is a British industrial services company specialising in decommissioning of ships and offshore installations.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
NABL vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $130.3M | $70.6M |
| Net Profit | — | $-34.6M |
| Gross Margin | 76.2% | — |
| Operating Margin | 10.2% | -56.7% |
| Net Margin | — | -49.0% |
| Revenue YoY | 11.8% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $130.3M | — | ||
| Q3 25 | $131.7M | $70.6M | ||
| Q2 25 | $131.2M | — | ||
| Q1 25 | $118.2M | — | ||
| Q4 24 | $116.5M | — | ||
| Q3 24 | $116.4M | — | ||
| Q2 24 | $119.4M | — | ||
| Q1 24 | $113.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | $1.4M | $-34.6M | ||
| Q2 25 | $-4.0M | — | ||
| Q1 25 | $-7.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $10.8M | — | ||
| Q2 24 | $9.5M | — | ||
| Q1 24 | $7.5M | — |
| Q4 25 | 76.2% | — | ||
| Q3 25 | 77.5% | — | ||
| Q2 25 | 78.1% | — | ||
| Q1 25 | 76.6% | — | ||
| Q4 24 | 80.0% | — | ||
| Q3 24 | 82.9% | — | ||
| Q2 24 | 84.0% | — | ||
| Q1 24 | 83.9% | — |
| Q4 25 | 10.2% | — | ||
| Q3 25 | 8.8% | -56.7% | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 13.7% | — | ||
| Q3 24 | 20.5% | — | ||
| Q2 24 | 18.4% | — | ||
| Q1 24 | 18.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.1% | -49.0% | ||
| Q2 25 | -3.1% | — | ||
| Q1 25 | -6.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 7.9% | — | ||
| Q1 24 | 6.6% | — |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $-0.02 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $0.01 | — | ||
| Q3 24 | $0.06 | — | ||
| Q2 24 | $0.05 | — | ||
| Q1 24 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $111.8M | $490.9M |
| Total DebtLower is stronger | $393.9M | — |
| Stockholders' EquityBook value | $804.7M | $503.0M |
| Total Assets | $1.4B | $577.1M |
| Debt / EquityLower = less leverage | 0.49× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $111.8M | — | ||
| Q3 25 | $101.4M | $490.9M | ||
| Q2 25 | $93.9M | — | ||
| Q1 25 | $94.1M | — | ||
| Q4 24 | $85.2M | — | ||
| Q3 24 | $174.4M | — | ||
| Q2 24 | $157.5M | — | ||
| Q1 24 | $139.2M | — |
| Q4 25 | $393.9M | — | ||
| Q3 25 | $331.7M | — | ||
| Q2 25 | $332.1M | — | ||
| Q1 25 | $332.6M | — | ||
| Q4 24 | $333.1M | — | ||
| Q3 24 | $333.6M | — | ||
| Q2 24 | $334.1M | — | ||
| Q1 24 | $334.5M | — |
| Q4 25 | $804.7M | — | ||
| Q3 25 | $813.4M | $503.0M | ||
| Q2 25 | $809.4M | — | ||
| Q1 25 | $775.1M | — | ||
| Q4 24 | $759.3M | — | ||
| Q3 24 | $765.0M | — | ||
| Q2 24 | $724.4M | — | ||
| Q1 24 | $709.1M | — |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $577.1M | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.46× | — | ||
| Q1 24 | 0.47× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $25.3M | $-84.6M |
| Free Cash FlowOCF − Capex | $20.9M | $-84.7M |
| FCF MarginFCF / Revenue | 16.0% | -120.1% |
| Capex IntensityCapex / Revenue | 3.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $75.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.3M | — | ||
| Q3 25 | $24.0M | $-84.6M | ||
| Q2 25 | $24.2M | — | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | $26.0M | — | ||
| Q3 24 | $22.0M | — | ||
| Q2 24 | $27.3M | — | ||
| Q1 24 | $4.2M | — |
| Q4 25 | $20.9M | — | ||
| Q3 25 | $17.4M | $-84.7M | ||
| Q2 25 | $20.4M | — | ||
| Q1 25 | $16.4M | — | ||
| Q4 24 | $18.8M | — | ||
| Q3 24 | $18.2M | — | ||
| Q2 24 | $24.0M | — | ||
| Q1 24 | $746.0K | — |
| Q4 25 | 16.0% | — | ||
| Q3 25 | 13.2% | -120.1% | ||
| Q2 25 | 15.5% | — | ||
| Q1 25 | 13.9% | — | ||
| Q4 24 | 16.2% | — | ||
| Q3 24 | 15.7% | — | ||
| Q2 24 | 20.1% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 3.4% | — | ||
| Q3 25 | 5.0% | 0.2% | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 3.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 17.36× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.04× | — | ||
| Q2 24 | 2.89× | — | ||
| Q1 24 | 0.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NABL
| Transferred Over Time | $121.9M | 94% |
| Transferred At Point In Time | $8.4M | 6% |
| Other Revenue | $1.3M | 1% |
VRDN
Segment breakdown not available.
